Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain.

abstract：:Mapping functions are estimated using regression analyses and are frequently used to predict health state utility values (HSUVs) in decision analytic models. Mapping functions are used when evidence on the required preference-based measure (PBM) is not available, or where modelled values are required for a decision an...

journal_title：PharmacoEconomics

authors： Ara R,Rowen D,Mukuria C

更新日期：2017-12-01 00:00:00

abstract：:Studies have not previously reported the indirect cost burden of multiple sclerosis (MS) from an employer perspective. To compare annual indirect costs between privately insured US employees with MS and matched employee controls. A retrospective analysis of a privately insured claims database containing disability dat...

journal_title：PharmacoEconomics

authors： Ivanova JI,Birnbaum HG,Samuels S,Davis M,Phillips AL,Meletiche D

更新日期：2009-01-01 00:00:00

abstract：:A survey of the prescribing of psychotropic drugs was carried out at the Psychiatric Hospital of Bahrain. This retrospective study on 60 inpatients of the Long Stay Ward revealed a man:woman ratio of 2.7. 91% of the men and 88% of the women were over 40 years old. 44 of the 60 patients had a diagnosis of schizophre...

journal_title：PharmacoEconomics

authors： El Hefny F,Al Haddad MK,Mathur V

更新日期：1992-03-01 00:00:00

abstract：:The application of cost-effectiveness methodology is particularly important in widespread diseases such as hypertension. However, because prospective cost-effectiveness analyses comparing different antihypertensive drugs are not currently available, differences in the cost effectiveness of these drugs can only be esti...

journal_title：PharmacoEconomics

authors： Van Bortel LM,Ament AJ

更新日期：1995-12-01 00:00:00

abstract：:Epilepsy is a chronic condition with numerous social and psychological consequences. This work aimed to review available data on epilepsy and the impact of surgical and pharmaceutical treatments on the quality of life in adults and children. Research on quality of life in epilepsy is characterised by a wide and fragme...

journal_title：PharmacoEconomics

authors： Berto P

更新日期：2002-01-01 00:00:00

abstract：OBJECTIVE:To examine the relative cost effectiveness of topical calcipotriol and short-contact dithranol in the treatment of mild to moderate plaque psoriasis. DESIGN AND SETTING:This was a modelling study from the perspective of the UK National Health Service as payer. METHODS:The interventions were compared using 2...

journal_title：PharmacoEconomics

authors： Ashcroft DM,Li Wan Po A,Williams HC,Griffiths CE

更新日期：2000-11-01 00:00:00

abstract：:The objective of this study was to compare the cost effectiveness of amoxicillin/clavulanic acid with other antibacterial regimens for prophylaxis of infection after elective abdominal or gynaecological surgery. Data from 21 previously published comparative clinical trials were used to calculate statistical confidence...

journal_title：PharmacoEconomics

authors： Davey PG,Parker SE,Crombie IK,Jaderberg M

更新日期：1995-04-01 00:00:00

abstract：:Epidural analgesia and intravenous analgesia with opioids are two techniques for providing pain relief for women in labour. Labour pain is comparable to surgical pain in its severity, and epidural analgesia provides better relief from this pain than intravenous analgesia; a meta-analysis quantified this improvement to...

journal_title：PharmacoEconomics

authors： Huang C,Macario A

更新日期：2002-01-01 00:00:00

abstract：:Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the relief of the symptoms of osteoarthritis (OA), rheumatoid arthritis (RA), sprains and strains, sports injuries and menstrual disorders, and have a small role in the management of patent ductus arteriosus in the neonate. In patients with RA, symptom...

journal_title：PharmacoEconomics

authors： Wynne HA,Campbell M

更新日期：1993-02-01 00:00:00

abstract：OBJECTIVE:Cost is an issue when prescribing two drugs with equivalent efficacy. We compared the direct medical costs of topical brinzolamide 1% (twice a day or three times daily) with topical dorzolamide 2% (twice a day or three times daily) in France, Italy, Portugal and Spain in patients with ocular hypertension or p...

journal_title：PharmacoEconomics

authors： Rouland JF,Le Pen C,Gouveia Pinto C,Berto P,Berdeaux G

更新日期：2003-01-01 00:00:00

abstract：:For practical reasons, in order to carry out economic evaluations of collective decisions, total costs will generally be compared with total benefits; hence, individuals' willingness to pay (WTP) or quality-adjusted life-years (QALYs) have to be estimated at an aggregate level. So far, aggregation has usually been don...

journal_title：PharmacoEconomics

authors： Liljas B,Lindgren B

更新日期：2001-01-01 00:00:00

abstract：:There is an inevitable tension between robust reimbursement processes and providing speedy access to new and novel technologies, given uncertainties about key pieces of evidence and subsequent concerns regarding their overall efficiency. The public perception of these treatments as 'breakthrough', combined with substa...

journal_title：PharmacoEconomics

authors： McCabe CJ,Stafinski T,Edlin R,Menon D,Banff AED Summit.

更新日期：2010-01-01 00:00:00

abstract：OBJECTIVE:To determine whether the use of risperidone in a US managed-care environment is associated with a reduction in the use of mental healthcare services. METHODS:Mental health service use and costs for patients with psychoses treated with risperidone versus those treated with conventional antipsychotic agents we...

journal_title：PharmacoEconomics

authors： Gianfrancesco F,Durkin MB,Mahmoud R,Wang RH

更新日期：2002-01-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to evaluate the cost effectiveness of no prophylaxis, primary prophylaxis (PP), or secondary prophylaxis (SP) with granulocyte colony-stimulating factors (G-CSFs), i.e., pegfilgrastim, lipegfilgrastim, filgrastim (6- and 11-day), or lenograstim (6- and 11-day), to reduce the in...

journal_title：PharmacoEconomics

authors： Fust K,Li X,Maschio M,Villa G,Parthan A,Barron R,Weinstein MC,Somers L,Hoefkens C,Lyman GH

更新日期：2017-04-01 00:00:00

abstract：OBJECTIVE:To estimate savings in the cost of caring for patients with Alzheimer's disease (AD) during 6 months, 1 year and 2 years of treatment with rivastigmine. An intermediate objective was to estimate the relationship between disease progression and institutionalisation. DESIGN AND SETTING:We assessed the relation...

journal_title：PharmacoEconomics

authors： Hauber AB,Gnanasakthy A,Snyder EH,Bala MV,Richter A,Mauskopf JA

更新日期：2000-04-01 00:00:00

abstract：:Productivity costs are frequently omitted from economic evaluations, despite their often strong impact on cost-effectiveness outcomes. This neglect may be partly explained by the lack of standardization regarding the methodology of estimating productivity costs. This paper aims to contribute to standardization of prod...

journal_title：PharmacoEconomics

authors： Krol M,Brouwer W

更新日期：2014-04-01 00:00:00

abstract：:Although decision making about what drugs to include in an institutional formulary appears to lend itself readily to quantitative techniques such as decision analysis and cost-benefit analysis, a review of the literature reveals that very little has been published in this area. Several of the published decision analy...

journal_title：PharmacoEconomics

authors： Schechter CB

更新日期：1993-06-01 00:00:00

abstract：BACKGROUND:In Ireland, all new drugs are considered for a formal pharmacoeconomic evaluation (PE) prior to a reimbursement decision. All evaluations are conducted by the National Centre for Pharmacoeconomics (NCPE). The objectives of this study were to describe the evaluation process and to examine the movement of drug...

journal_title：PharmacoEconomics

authors： McCullagh L,Barry M

更新日期：2016-12-01 00:00:00

abstract：:To review and critically evaluate published cost-utility analyses (CUAs) pertaining to pharmaceuticals for the past 3 decades. We examined data from the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org), which contains detailed information on English-language CUAs and their ratios (in $US...

journal_title：PharmacoEconomics

authors： Neumann PJ,Fang CH,Cohen JT

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:The measurement and valuation of health-related quality of life for and by young people are increasingly important, yet research on the impact of study perspective and validity of preferences obtained from young populations remains limited. OBJECTIVE:The objective of this study was to evaluate the feasibili...

journal_title：PharmacoEconomics

authors： Dalziel K,Catchpool M,García-Lorenzo B,Gorostiza I,Norman R,Rivero-Arias O

更新日期：2020-05-01 00:00:00

abstract：BACKGROUND:Potential differences in toxicity, potency and acquisition price among the liposomal amphotericin B formulations makes it unclear which agent is less costly when total resource consumption and treatment-associated costs are considered. DESIGN:A retrospective cost-minimisation analysis in 51 patients was per...

journal_title：PharmacoEconomics

authors： Kuti JL,Kotapati S,Williams P,Capitano B,Nightingale CH,Nicolau DP

更新日期：2004-01-01 00:00:00

abstract：:This article examines the twin concepts of the statistical significance and quantitative importance of observed differences in studies comparing medicines in terms of economic parameters such as cost-effectiveness and measures of health-related quality of life (HRQOL). Central to the design and interpretation of any ...

journal_title：PharmacoEconomics

authors： O'Brien BJ,Drummond MF

更新日期：1994-05-01 00:00:00

abstract：BACKGROUND:In Australia, many patients who are initiated on asthma controller inhalers receive combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) despite having asthma of sufficiently low severity that ICS-alone would be equally effective and less costly for the government. METHODS:We conducted a ...

journal_title：PharmacoEconomics

authors： Laba TL,Reddel HK,Zwar NJ,Marks GB,Roughead E,Flynn A,Goldman M,Heaney A,Lembke K,Jan S

更新日期：2019-02-01 00:00:00

abstract：BACKGROUND:The process of "mapping" is increasingly being used to predict health utilities, for application within health economic evaluations, using data on other indicators or measures of health. Guidance for the reporting of mapping studies is currently lacking. OBJECTIVE:The overall objective of this research was ...

journal_title：PharmacoEconomics

authors： Petrou S,Rivero-Arias O,Dakin H,Longworth L,Oppe M,Froud R,Gray A

更新日期：2015-10-01 00:00:00

abstract：:The manufacturer of olaratumab (Lartruvo®), Eli Lilly & Company Limited, submitted evidence for the clinical and cost effectiveness of this drug, in combination with doxorubicin, for untreated advanced soft tissue sarcoma (STS) not amenable to surgery or radiotherapy, as part of the National Institute for Health and C...

journal_title：PharmacoEconomics

authors： Tikhonova IA,Jones-Hughes T,Dunham J,Warren FC,Robinson S,Stephens P,Hoyle M

更新日期：2018-01-01 00:00:00

abstract：OBJECTIVE:The aim of this study was to develop a generic treatment algorithm for influenza and influenza-like illness (ILI) that could be used to estimate the costs and outcomes of current and new treatments for influenza in different countries for different patient subgroups. METHODS:A series of possible treatment pa...

journal_title：PharmacoEconomics

authors： Mauskopf JA,Cates SC,Griffin AD

更新日期：1999-01-01 00:00:00

abstract：:In the current climate of cost containment and quality control, nosocomial infection is a worrisome adverse event in hospital care. Hospitalised patients require care for increasingly severe illnesses, and are therefore more susceptible to infection, especially by opportunistic micro-organisms. It is thus necessary to...

journal_title：PharmacoEconomics

authors： Gálvez-Vargas R,Bueno-Cavanillas A,García-Martín M

更新日期：1995-02-01 00:00:00

abstract：:Constipation is one of the most common digestive complaints. It is a symptom, not a disease. The subjectivity that this involves means that assessments of clinical epidemiology, socioeconomic costs and pharmacotherapy are difficult, since there is no definition of 'normal' bowel habit. Although constipation can affect...

journal_title：PharmacoEconomics

authors： Passmore AP

更新日期：1995-01-01 00:00:00

abstract：:Scientific reviewing methods were applied to economic studies of influenza vaccination, and an economic model of influenza vaccination was developed from these primary sources. Issues arising from the secondary literature review include the quality of evidence on the effectiveness of the vaccines, the absence of a tra...

journal_title：PharmacoEconomics

authors： Jefferson T,Demicheli V

更新日期：1996-01-01 00:00:00

abstract：:Open-heart surgery (OHS) is performed to bypass occluded arteries, replace malfunctioning cardiac valves or correct congenital abnormalities. The average cost of OHS varies from $US25 057-$US79 795 (1997 values). The objective of this paper was to review economic studies of pharmacological strategies in open-heart sur...

journal_title：PharmacoEconomics

authors： Reddy P,Song J

更新日期：2003-01-01 00:00:00